University of California, San Diego | UCSD Moores Cancer Center
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.
Full description
This is a two-part, open-label, multi-center, dose escalation and dose expansion study in participants with BRAF mutation-positive and/or NRAS mutation-positive tumors designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of KIN-2787, a RAF small molecule kinase inhibitor, to determine a recommended Phase 2 dose (RP2D) of KIN-2787, and to assess the objective response to KIN-2787 therapy alone and in combination with binimetinib, a mitogen-activated protein kinase (MEK) inhibitor.
The dose expansion phase (Part B) will assess the safety and efficacy of KIN-2787 at the recommended dose and schedule in patients with cancers that contain BRAF Class I, II or III mutations, including lung cancer, melanoma, and other selected solid tumors.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Complete inclusion and exclusion criteria are listed in the clinical study protocol.
Primary purpose
Allocation
Interventional model
Masking
400 participants in 4 patient groups
Loading...
Central trial contact
Claire Fabre, MD; Moutaffian Helene, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal